Vyome Holdings Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing innovative dermatology therapies, particularly for antibiotic-resistant acne and other inflammatory skin diseases, using microbiome science, molecular diagnostics, and precision medicine approaches to create targeted, resistance-aware treatments. The company aims to reduce reliance on broad-spectrum antibiotics by designing pathogen-specific therapies that improve efficacy while preserving the natural skin microbiome. Vyome later combined with ReShape Lifesciences, a publicly traded medical device company historically focused on weight-loss and metabolic health solutions, expanding the combined organizations strategic scope to include biopharmaceutical dermatology alongside its established medical technology portfolio. Together, the entities reflect a diversified healthcare platform spanning medical devices and precision-driven therapeutic development.
